FrancophonIA/ELRC3.0 huggingface dataset:
English: In this study, patients reported that they were ‘satisfied' or ‘very satisfied' with PecFent treatment for around 90% of breakthrough pain episodes.
Estonian: Patsiendid olid selles uuringus PecFenti raviga rahul või väga rahul 90%-l läbimurdevalu episoodidest.
English: PecFent contains the active substance fentanyl.
Estonian: PecFent sisaldab toimeainena fentanüüli.
English: PecFent is used in patients who are already using opioids (a group of painkillers that includes morphine and fentanyl) to control long-term cancer pain.
Estonian: PecFenti kasutatakse vähivalu pikaajaliseks ohjamiseks opioide (rühm valuvaigisteid, mille hulka kuuluvad morfiin ja fentanüül) juba kasutavatel patsientidel.
English: An additional study measured the ‘acceptability' of PecFent by the patients, rating how satisfied they were with PecFent, and how easy and convenient they found it to use.
Estonian: Lisauuringus mõõdeti PecFenti vastuvõetavust patsientidele, milles patsiendid hindasid PecFentiga rahuolu ning kasutamise lihtsust ja mugavust.
English: An overview of PecFent and why it is authorised in the EU
Estonian: Ülevaade ravimist PecFent ja ELis müügiloa väljastamise põhjendus
English: What benefits of PecFent have been shown in studies?
Estonian: Milles seisneb uuringute põhjal PecFenti kasulikkus?
English: In one main study, PecFent was shown to be more effective than placebo (a dummy treatment) at treating breakthrough cancer pain in 83 adults who were being treated with opioids.
Estonian: Ühes põhiuuringus, milles osales 83 opioidravi saavat täiskasvanud patsienti, näidati, et PecFent on vähi läbimurdevalu ravimisel efektiivsem kui platseebo (näiv ravim).
English: Treatment with PecFent should be started by and remain under the supervision of a doctor who has experience in managing opioid treatment in cancer patients.
Estonian: Ravi PecFentiga peab alustama ja jälgima vähiga patsientide opioidravis kogenud arst.
English: Typical opioid side effects are to be expected with PecFent; often these will stop or become less intense with continued use of the medicine.
Estonian: Ravimi püsival kasutamisel need kõrvalnähud sageli kaovad või muutuvad nõrgemaks.
English: The first trial dose should always be 100 micrograms (one spray into one nostril).
Estonian: 100 g (üks pihustus ühte ninasõõrmesse).
English: For the full list of side effects reported with PecFent, see the package leaflet.
Estonian: PecFenti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Once in the bloodstream, fentanyl acts on receptors in the brain and spinal cord to relieve pain.
Estonian: Vereringes olev fentanüül toimib pea- ja seljaaju retseptoritesse, vaigistades valu.
English: The active substance in PecFent, fentanyl, is an opioid.
Estonian: PecFenti toimeaine fentanüül on opioid.
English: How does PecFent work?
Estonian: Kuidas PecFent toimib?
English: What is Begedina?
Estonian: Mis on Begedina?
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22 July 2016
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22.
English: There were also deficiencies identified in the manufacturing process of the medicine.
Estonian: Ka ravimi tootmisprotsessis tuvastati puudusi.
English: In the studies, Begedina was not compared with any other treatment.
Estonian: Neis uuringutes ei võrreldud Begedinat ühegi muu raviga.
English: Withdrawal of the marketing authorisation application for Begedina (begelomab) EMA/579473/2016
Estonian: Müügiloa taotluse tagasivõtmise teave: Begedina (begelomaab) EMA/579470/2016
English: The company presented the results of two studies with Begedina involving a total of 29 adults with acute graft-versus-host disease that did not respond to steroid treatment.
Estonian: Ettevõte esitas kahe Begedinaga tehtud uuringu tulemused, milles osales kokku 29 ägeda siiriku äratõukereaktsiooniga täiskasvanut, kellel ei tekkinud steroididega ravivastust.
English: The medicine was for use in patients whose disease did not respond to treatment with steroids.
Estonian: Ravimit kavatseti kasutada patsientidel, kellel ei tekkinud steroididega ravivastust.
English: Begedina is a medicine that contains the active substance begelomab.
Estonian: Begedina on ravim, mis sisaldab toimeainena begelomaabi.
English: In its letter notifying the Agency of the withdrawal of application, the company stated that it acknowledges the need to obtain additional data from a confirmatory study.
Estonian: Ettevõtte tunnistas kirjas, milles teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, vajadust saada kinnitavast uuringust täiendavaid andmeid.
English: Begedina was expected to be used for the treatment of acute graft-versus-host disease (a condition in which transplanted cells attack the patient's body) in adults who have had haematopoietic progenitor cell transplantation (transplant of cells that can develop into different types of blood cells) from a donor.
Estonian: Begedinat kavatseti kasutada ägeda siiriku äratõukereaktsiooni (olukord, kus siiratud rakud ründavad organismi) raviks täiskasvanutel, kellele on siiratud doonorilt saadud vereloome eellasrakke (rakud, millest tekivad teist tüüpi vererakud).
English: Begedina was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 26 November 2010 for treatment of graft-versus-host disease.
Estonian: Begedina nimetati 26. novembril 2010 siiriku äratõukereaktsiooni harvikravimiks (ravim, mida kasutatakse harvaesinevate haiguste korral).
English: In addition, the safety profile and the way the medicine is expected to work in the body had not been sufficiently characterised.
Estonian: Peale selle ei olnud piisavalt iseloomustatud ravimi ohutusprofiili ja ravimi eeldatavat toimeviisi organismis.
English: Withdrawal of the marketing authorisation application for Begedina (begelomab)
Estonian: Müügiloa taotluse tagasivõtmise teave: Begedina (begelomaab)
English: On 4 July 2016, Adienne S.r.l.
Estonian: Adienne S.r.l.
English: The active substance in Begedina, begelomab, is a monoclonal antibody (a type of protein) that has been designed to attach itself to a receptor called CD26, which is present on T cells.
Estonian: Begedina toimeaine begelomaab on monoklonaalne antikeha (teatud valk), mis on välja töötatud seonduma T-lümfotsüütide pinnal oleva retseptoriga CD26.
English: By attaching to CD26, this medicine is expected to reduce the rate at which the T cells multiply.
Estonian: CD26 valguga seondudes aeglustab see ravim eeldatavalt Tlümfotsüütide paljunemist.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not provided enough data to support the application for Begedina.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ettevõte ei ole esitanud piisavalt andmeid ravimi Begedina taotluse toetuseks.
English: The CHMP considered that the data provided were insufficient to demonstrate a beneficial effect of Begedina.
Estonian: Inimravimite komitee oli arvamusel, et Begedina kasulikkuse tõendamiseks esitatud andmed ei ole piisavad.
English: Based on the review of the available data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Begedina could not have been approved for the treatment of acute graft-versus-host disease that did not respond to steroid treatment.
Estonian: Tuginedes esitatud andmete analüüsile, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et Begedina kasutamist ägeda, steroidravile allumatu siiriku äratõukereaktsiooni raviks ei ole võimalik heaks kiita.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials with Begedina.
Estonian: Ettevõte teatas inimravimite komiteele, et praegu Begedina kliinilistes uuringutes osalevatele patsientidele taotluse tagasivõtmine mõju ei avalda.
English: How was Begedina expected to work?
Estonian: Milline on Begedina eeldatav toime?
English: activity of T cells from the transplant that attack the patient's organs, thereby helping to control graftversus-host disease.
Estonian: Siirikust pärinevate ja patsiendi elundeid ründavate T-lümfotsüütide arvu ja aktiivsust vähendades aitab see siiriku äratõukereaktsiooni ohjata.
English: These are a type of white blood cells that play a role in graft-versus-host disease.
Estonian: T-lümfotsüüdid on teatud vere valgelibled, mis osalevad siiriku äratõukereaktsioonis.
English: It was to be available as a concentrate to be made into a solution for infusion (drip) into a vein.
Estonian: Seda kavatseti turustada veenisiseselt manustatava infusioonilahuse kontsentraadina.
English: officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Begedina, for the treatment of graft-versus-host disease.
Estonian: teatas 4. juulil 2016 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Begedina müügiloa taotlus.
English: What was Begedina expected to be used for?
Estonian: Milleks kavatseti Begedinat kasutada?
English: 17 December 2012
Estonian: 17. detsember 2012
English: Page 2/2
Estonian: Lk. 2/2
English: The referral procedure started on 12 October 2011.
Estonian: Esildise menetlemine algas 12. oktoobril 2011.
English: 1 Article 35 of Directive 2001/82/EC, as amended
Estonian: 1 Muudetud direktiivi 2001/82/EÜ artikkel 35
English: Veterinary Medicines and Product Data Management
Estonian: Veterinaarravimid ja tooteandmete haldamine
English: The final opinion was converted into a Decision by the European Commission on 17 December 2012.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 17. detsembril 2012.
English: International non-proprietary name (inn): enrofloxacin Background information
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): enrofloksatsiin Taustteave
English: It has antibacterial activity against a broad spectrum of Gram-negative and Grampositive bacteria.
Estonian: Sellel on antibakteriaalne toime mitmesuguste gramnegatiivsete ja grampositiivsete bakterite vastu.
English: Supplementary information was provided in writing by an applicant and marketing authorisation holders on 16 January 2012.
Estonian: Taotleja ja müügiloa hoidjad esitasid lisateabe kirjalikult 16. jaanuaril 2012.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II.
Estonian: Asjaomaste raviminimetuste loetelu on I lisas ja teaduslikud järeldused II lisas.
English: The Committee appointed Dr M. Holzhauser-Alberti as rapporteur and Dr C. Muñoz Madero as co-rapporteur.
Estonian: Veterinaarravimite komitee määras hindajaks dr M. Holzhauser-Alberti ja kaashindajaks dr C. Muñoz Madero.
English: Enrofloxacin is for veterinary use only.
Estonian: Enrofloksatsiin on üksnes veterinaarseks kasutamiseks.
English: The dosage is 10 mg enrofloxacin per kg bodyweight during 5 days.
Estonian: Annus on 10 mg enrofloksatsiini kehamassi kg kohta 5 päeva jooksul.
English: On 14 May 2012, the European Commission requested the CVMP to review its opinion, mainly to clarify some aspects related to antimicrobial resistance and the prudent use of antimicrobials in veterinary medicine.
Estonian: 14. mail 2012 palus Euroopa Komisjon veterinaarravimite komiteel oma arvamus üle vaadata, peamiselt selleks, et selgitada mõningaid aspekte seoses antimikroobse resistentsuse ja antimikroobsete ravimite mõistliku kasutamisega veterinaarmeditsiinis.
English: HIPRALONA ENRO-S and its generics are veterinary medicinal products which contain enrofloxacin as active substance, and are indicated in rabbits for the treatment of respiratory infections caused by Pasteurella multocida.
Estonian: HIPRALONA ENRO-S ja selle geneerilised ravimid on veterinaarravimid, mis sisaldavad toimeainena enrofloksatsiini ning on näidustatud küülikutel Pasteurella multocida põhjustatud respiratoorsete infektsioonide raviks.
English: Enrofloxacin is a synthetic chemotherapeutic agent from the class of the fluoroquinolone carboxylic acid derivatives.
Estonian: Enrofloksatsiin on sünteetiline kemoterapeutikum, mis kuulub fluorokinolooni karboksüülhappe derivaatide klassi.
English: On 30 September 2011, France initiated a referral procedure under Article 35 of Directive 2001/82/EC, as amended, for the veterinary medicinal product HIPRALONA ENRO-S and its generics indicated for use in rabbits, due to concerns that the use of the products in rabbit production would increase Escherichia coli and Staphylococcus aureus resistance to enrofloxacin.
Estonian: 30. septembril 2011 algatas Prantsusmaa veterinaarravimi HIPRALONA ENRO-S ja selle geneeriliste ravimite kohta (näidustatud küülikutel kasutamiseks) muudetud direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse, sest oletati, et nende ravimite kasutamine küülikutel suurendab Escherichia coli ning Staphylococcus aureus'e resistentsust enrofloksatsiini suhtes.
English: The pharmaceutical form is an oral solution administered via the drinking water.
Estonian: Ravimvorm on suukaudne lahus, mida manustatakse joogiveega.
English: Based on the evaluation of the available data, on 11 April 2012, the CVMP adopted by majority an opinion recommending the maintenance of the marketing authorisations for the veterinary medicinal product HIPRALONA ENRO-S and its generics in accordance with the previously approved product information.
Estonian: Olemasolevate andmete hindamisel võttis veterinaarravimite komitee 11.aprillil 2012 häälteenamusega vastu otsuse, mis soovitab veterinaarravimi HIPRALONA ENRO-S ja selle geneeriliste ravimite müügiload varem heakskiidetud ravimiteabe kohaselt säilitada.
English: On 13 September 2012, the CVMP adopted by majority a revised opinion confirming the recommendation, included in its opinion of 11 April 2012, that the marketing authorisations for the veterinary medicinal product HIPRALONA ENRO-S and its generics should be maintained in accordance with the previously approved product information.
Estonian: 13. septembril 2012 võttis veterinaarravimite komitee häälteenamusega vastu ülevaadatud arvamuse, mis kinnitab komitee 11. aprilli 2012 arvamuses sisalduvat soovitust veterinaarravimi HIPRALONA ENRO-S ja selle geneeriliste ravimite müügiload varem heakskiidetud ravimiteabe kohaselt säilitada.
English: Always take Enviage exactly as your doctor has told you.
Estonian: Võtke Enviage't alati täpselt nii, nagu arst on teile rääkinud.
English: If you forget to take Enviage
Estonian: Kui te unustate Enviage't võtta
English: Do not take Enviage if you are pregnant.
Estonian: Ärge võtke Enviage't, kui te olete rase.
English: Taking Enviage with food and drink
Estonian: Enviage võtmine koos toidu ja joogiga
English: Like all medicines, Enviage can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka Enviage põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: Enviage is not recommended for use in children and adolescents below age 18 due to a lack of data on safety and efficacy (see section 5.2).
Estonian: Enviage't ei soovitata kasutada lastel ja noorukitel vanuses alla 18 aasta ohutuse ja efektiivsuse andmete puudumise tõttu (vt lõik 5.2).
English: Enviage has been evaluated for safety in more than 7,800 patients, including over 2,300 treated for over 6 months, and more than 1,200 for over 1 year.
Estonian: Enviage ohutust on hinnatud enam kui 7800 patsiendil, kellest enam kui 2300 on ravi saanud üle 6 kuu ja enam kui 1200 üle 1 aasta.
English: If you have accidentally taken too many Enviage tablets, consult a doctor immediately.
Estonian: Kui te olete kogemata võtnud liiga palju Enviage tablette, pidage otsekohe nõu arstiga.
English: This condition should be corrected prior to administration of Enviage, or the treatment should start under close medical supervision.
Estonian: See seisund tuleb korrigeerida enne Enviage manustamist või tuleb ravi alustada hoolika meditsiinilise jälgimise all.
English: Do not use Enviage after the expiry date which is stated on the carton and blister.
Estonian: Ärge kasutage Enviage't pärast kõlblikkusaega, mis on märgitud karbil ja blistril.
English: Enviage belongs to a new class of medicines called renin inhibitors.
Estonian: Enviage kuulub uude ravimite rühma, mida nimetatakse reniini inhibiitoriteks.
English: If you forget to take a dose of Enviage, take it as soon as you remember and then take the next dose at its usual time.
Estonian: Kui te unustate Enviage annuse võtmata, võtke see niipea kui meelde tuleb ning seejärel võtke järgmine annus tavalisel ajal.
English: The MAH must ensure that the system of pharmacovigilance, as described in version 8.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Estonian: Müügiloa hoidja peab tagama, et ravimohutuse järelvalve süsteem, nagu on kirjeldatud müügiloa taotluse moodulis 1.8.1 esitatud versioonis 8.0, on loodud ja toimib enne toote turuletulekut ja toote turustamise ajal.
English: Before you drive a vehicle, use machinery, or carry out other activities that require concentration, you should make sure you know how you react to the effects of Enviage.
Estonian: Enne autojuhtimist, masinatega töötamist või muude keskendumist nõudvate tegevuste sooritamist veenduge, et te teate, kuidas Enviage teile mõjub.
English: If any of these apply to you, tell your doctor before you take Enviage.
Estonian: Kui midagi eelnevast kehtib teie kohta, öelge seda arstile enne Enviage võtmist.
English: If you take more Enviage than you should
Estonian: Kui te võtate Enviage't rohkem kui ette nähtud
English: Enviage has been studied in 1,864 patients aged 65 years or older, and in 426 patients aged 75 years or older.
Estonian: Enviage kasutamist on uuritud 1864-l 65-aastasel ja vanemal patsiendil ning 426-l 75-aastasel ja vanemal patsiendil.
English: Do not take Enviage - if you are allergic (hypersensitive) to aliskiren or any of the other ingredients of Enviage.
Estonian: Ärge võtke Enviage't - kui te olete allergiline (ülitundlik) aliskireeni või Enviage mõne koostisosa suhtes.
English: Preliminary data suggest that irbesartan may decrease Enviage AUC and Cmax.
Estonian: Esialgsed andmed näitavad, et irbesartaaniga võib väheneda Enviage AUC ja Cmax.
English: The use of Enviage in children and adolescents is not recommended.
Estonian: Enviage't ei soovitata kasutada lastel ja noorukitel.
English: In diabetic hypertensive patients, Enviage monotherapy was safe and effective.
Estonian: Suhkurtõvega hüpertensiivsetel patsientidel oli Enviage monoteraapia ohutu ja efektiivne.
English: If angioedema occurs, Enviage should be promptly discontinued and appropriate therapy and monitoring provided until complete and sustained resolution of signs and symptoms has occurred.
Estonian: Angioödeemi tekkimisel tuleb Enviage kasutamine kohe lõpetada ning alustada sobivat ravi ja jälgimist kuni sümptomite täieliku ja püsiva taandumiseni.
English: Enviage helps to lower high blood pressure.
Estonian: Enviage aitab langetada kõrgenenud vererõhku.
English: Food intake Meals with a high fat content have been shown to reduce the absorption of Enviage substantially.
Estonian: Toit Suure rasvasisaldusega toidud on oluliselt vähendanud Enviage imendumist.
English: You should take Enviage with a light meal once a day, preferably at the same time each day.
Estonian: Te peate Enviage't võtma koos kerge einega üks kord ööpäevas, soovitatavalt iga päev samal ajal.
English: Beneficial effects of Enviage on mortality and cardiovascular morbidity and target organ damage are currently unknown.
Estonian: Enviage kasulik toime suremusele ja kardiovaskulaarsele haigestumusele ning sihtorgani kahjustusele on praegu teadmata.
English: If pregnancy is detected during therapy, Enviage should be discontinued accordingly.
Estonian: Kui ravi ajal ilmneb rasedus, tuleb Enviage kasutamine järelikult lõpetada.
English: B-type natriuretic peptide (BNP) levels were reduced by 25% in the Enviage arm compared to placebo.
Estonian: B-tüüpi natriureetilise peptiidi (BNP) tasemed langesid Enviage poolel 25%, võrreldes platseeboga.
English: As for any medicine that acts directly on the RAS, Enviage should not be used during the first trimester of pregnancy or in women planning to become pregnant and is contraindicated during the second and third trimesters (see section 4.3).
Estonian: Nagu ka teisi otseselt RAS'i mõjutavaid ravimeid, ei tohi Enviage't kasutada raseduse esimese trimestri ajal või rasedust planeerivatel naistel ning ravim on vastunäidustatud raseduse teisel ja kolmandal trimestril (vt lõik 4.3).
English: Enviage should be taken with a light meal once a day, preferably at the same time each day.
Estonian: Enviage't tuleb võtta koos kerge einega üks kord ööpäevas, soovitatavalt iga päev samal ajal.
English: In this leaflet: What Enviage is and what it is used for
Estonian: MIS RAVIM ON ENVIAGE JA MILLEKS SEDA KASUTATAKSE
English: In a 3-month study of 302 patients with mild stable heart failure, all of whom were receiving standard therapy for stable heart failure, addition of Enviage 150 mg was well tolerated.
Estonian: 3-kuulises uuringus, kus osales 302 kerge stabiilse südamepuudulikkusega patsienti, kes said standardravi stabiilse südamepuudulikkuse korral, said lisaks Enviage 150 mg'i, mis osutus hästi talutavaks.
English: You should not take Enviage together with grapefruit juice.
Estonian: Enviage't ei tohi võtta koos greipfruudi mahlaga.
English: The incidence of cough was similar in placebo (0.6%) and Enviage treated (0.9%) patients.
Estonian: Köha esinemissagedus oli sarnane platseebot (0,6%) ja Enviage-ravi (0,9%) saanud patsientidel.
English: Enviage was not teratogenic in rats or rabbits (see section 5.3).
Estonian: Rottidel ja küülikutel ei olnud Enviage teratogeenne (vt lõik 5.3).
English: Enviage has no known clinically relevant interactions with medicinal products commonly used to treat hypertension or diabetes.
Estonian: Enviage'l puuduvad teadaolevad kliiniliselt olulised koostoimed ravimitega, mida sageli kasutatakse hüpertensiooni või diabeedi raviks.
English: In diabetic hypertensive patients, Enviage provided additive blood pressure reductions when added to ramipril, while the combination of Enviage and ramipril had a lower incidence of cough (1.8%) than ramipril (4.7%).
Estonian: Suhkurtõvega hüpertensiivsetel patsientidel viis Enviage lisamine ramipriilravile täiendava vererõhu languseni, samal ajal kui Enviage ja ramipriili kombinatsiooni kasutamisel oli köha esinemissagedus väiksem (1,8%) kui ramipriili kasutamisel (4,7%).
English: The proportion of patients who had UACR reduced at least 50% from baseline to endpoint was 24.7% and 12.5% for Enviage and placebo, respectively.
Estonian: Patsientide hulk, kellel albumiini ja kreatiniini suhe uriinis vähenes algpunktist lõpp-punktini vähemalt 50%'i võrra, oli Enviage korral 24,7% ja platseebo korral 12,5%.
English: In clinical studies Enviage has not been investigated in hypertensive patients with severe renal impairment (serum creatinine ≥ 150 μmol/l or 1.70 mg/dl in women and ≥ 177 μmol/l or 2.00 mg/dl in men and/or estimated glomerular filtration rate (GFR) < 30 ml/min), history of dialysis, nephrotic syndrome or renovascular hypertension.
Estonian: Kliinilistes uuringutes ei ole uuritud Enviage kasutamist hüpertensiivsetel patsientidel, kellel on raske neerukahjustus (seerumi kreatiniinisisaldus ≥ 150 µmol/l või 1,70 mg/dl naistel ja ≥ 177 µmol/l või 2,00 mg/dl meestel ja/või glomerulaarfiltratsiooni kiirus < 30 ml/min), anamneesis dialüüs, nefrootiline sündroom või renovaskulaarne hüpertensioon.
English: Your doctor may prescribe Enviage together with other medicines used to treat high blood pressure.
Estonian: Arst võib määrata Enviage koos teiste kõrgvererõhu ravimitega.
English: The recommended dose of Enviage is 150 mg once daily.
Estonian: Enviage soovitatav annus on 150 mg üks kord ööpäevas.
English: In experimental animals, it has been shown that P-gp is a major determinant of Enviage bioavailability.
Estonian: Katseloomadel on kindlaks tehtud, et Enviage biosaadavusel on määrava tähtsusega P-gp.